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Background: The rapid aging of the population in Japan has been accompanied by an increased rate of surgery
for lung cancer among elderly patients. It is thus an urgent priority to map out a treatment strategy for elderly
patients with primary lung cancer. Although surgical resection remains standard treatment for early stage
non–small-cell lung cancer (NSCLC), it is now essential to confirm the status of epidermal growth factor receptor
(EGFR) gene mutations when planning treatment strategies. Furthermore, several studies have reported that EGFR
mutations are an independent prognostic marker in NSCLC. However, the relations between age group and the
molecular and pathological characteristics of NSCLC remain unclear. We studied the status of EGFR mutations in
elderly patients with NSCLC and examined the relations of EGFR mutations to clinicopathological factors and
outcomes according to age group.
Methods: A total of 388 consecutive patients with NSCLC who underwent complete tumor resection in our
hospital from 2006 through 2008 were studied retrospectively. Formalin-fixed, paraffin-embedded tissue sections
were used to isolate DNA from carcinoma lesions. Mutational analyses of EGFR gene exons 19, 20, and 21 and KRAS
gene exons 12 and 13 were performed by loop-hybrid mobility shift assay, a highly sensitive polymerase chain
reaction-based method.
Results: EGFR mutations were detected in 185 (47.7%) and KRAS mutations were detected in 33 (8.5%) of the
388 patients. EGFR mutations were found in a significantly higher proportion of patients younger than 80 years
(younger group; 178/359, 49.6%) than in patients 80 years or older (older group; 7/29, 24.1%) (P = 0.008). In contrast,
KRAS mutations were more common in the older group (6/29, 20.7%) than in the younger group (27/359, 7.5%)
(P = 0.014). The older group showed a trend toward a higher rate of 5-year overall survival among elderly patients
with EGFR mutations (100%) than among those with wild-type EGFR (66.2%), but the difference was not significant.
Conclusions: Our results suggest that the EGFR status of patients with NSCLC differs between patients 80 years or
older and those younger than 80 years. EGFR mutation status might be a prognostic marker in elderly patients with
completely resected NSCLC.* Correspondence: t-nishii@kcch.jp
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Primary lung cancer remains the leading cause of the
death from malignant tumors worldwide [1]. Non–small-
cell lung cancer (NSCLC) accounts for approximately 80%
of all cases of lung cancer [2]. Although surgical resection
remains the standard treatment for early NSCLC, several
molecular pathways have been shown to have prognostic
significance in NSCLC. The epidermal growth factor
receptor (EGFR) pathway is considered particularly im-
portant. EGFR is a membrane glycoprotein with an
extracellular ligand-binding domain, a transmembrane
lipophilic segment, and an intracellular domain that
has tyrosine kinase activity. When a growth factor
binds to EGFR, EGFR is self-phosphorylated by tyro-
sine kinase, and phosphorylated EGFR activates cell-
signaling pathway involved in the regulation of cell
cycle, apoptosis, angiogenesis, and cellular prolifera-
tion. Specific mutations of EGFR induce constant
phosphorylation of EGFR, and increased levels of phos-
phorylated EGFR activate downstream signals that induce
carcinogenesis [3,4]. EGFR mutations predict the effect
of EGFR tyrosine kinase inhibitors (EGFR-TKI) [5,6]. It is
now essential to confirm EGFR mutation status when
planning treatment strategies for advanced or recurrent
NSCLC.
The population of Japan is aging rapidly. In 2011 the
average life-span in Japan was 83 years (males 79 years,
females 86 years) [7]. Aging of the population is accom-
panied by a rapid increase in the incidence of primary
lung cancer as well as the number of operations for lung
cancer among elderly patients. Since 2009 persons 80 years
or older have accounted for more than 10% of all patients
in Japan. In 2011, patients 80 years old or older accounted
for 11.5% of all patients [8-12]. Aging will become a global
problem in the future, and knowledge acquired in Japan
may contribute to solving related problems. Previous stud-
ies have suggested a relation between EGFR mutations
and several clinicopathological factors, but whether EGFR
status differs according to age group remains unclear. The
present study assessed the status of EGFR mutations in
elderly patients with NSCLC and examined the relations




We retrospectively studied 388 consecutive patients with
NSCLC who underwent complete tumor resection at
Kanagawa Cancer Center Hospital (Yokohama, Japan)
from 2006 through 2008. This study was approved by
the ethics committee of the Kanagawa Cancer Center,
and informed consent was obtained from all patients.
The pathological diagnoses were independently made by 2
pathologists (T.N., T.Y.). Discrepancies in diagnoses wereresolved by mutual agreement. The median follow-up
time was 1981 days.
Assessments
Formalin-fixed, paraffin-embedded tissue sections of
the resected tumors were used for DNA extraction.
Mutational analyses of EGFR gene exons 19, 20, and 21
and KRAS gene exons 12 and 13 were performed by
loop-hybrid mobility shift assay (LH-MSA), a highly sensi-
tive polymerase chain reaction–based method, as described
previously (Additional file 1: Table S1) [13].
Statistical analysis
Relations between EGFR status and categorical data were
evaluated with the chi-square test. Continuous variables
were compared by Student’s t-test. Survival curves were
plotted using the Kaplan-Meier method, and differences
in survival rates were assessed using the log-rank test.
P < 0.05 was considered to indicate statistical significance.
Statistical manipulations were performed using the IBM
SPSS Statistics 20 for Windows software system (IBM
Corp, Armonk, NY, USA).
Results
Relations between EGFR, KRAS status and
clinicopathological features
The patients’ characteristics are summarized in Table 1.
Of the 388 patients, 228 (58.8%) were men, and 160
(41.2%) were women. The mean age was 66.6 years
(range, 35–90). EGFR mutations were detected in 185
patients (185/388, 47.7%) and KRAS mutations were de-
tected in 33 (33/388, 8.5%). EGFR mutations were found
more frequently in women (110/185, 59.5%), adenocar-
cinoma (183/185, 98.9%), and non-smokers (106/185,
57.3%) (P < 0.001). Patients with EGFR mutation had
fewer pre-existing cardiopulmonary comorbidities than
patients with wild-type (P = 0.028). The mean tumor
diameter was smaller in patients with EGFR mutations
(2.68 ± 0.92 cm) than in those with wild-type EGFR
(3.35 ± 1.71 cm; P < 0.001). The rate of pathological T1
disease was significantly higher among patients with
EGFR mutations (114/185, 61.6%) than among those
with wild-type EGFR (83/203, 40.9%; P < 0.001). In contrast,
KRAS mutations were not significantly related to gender,
histopathological type, or smoking status. Although KRAS
status did not correlate with pathological T factors, mean
tumor diameter was larger in patients with KRAS muta-
tions (3.46 ± 1.99 cm) than in those with wild-type KRAS
(2.99 ± 1.36 cm; P = 0.001).
Relations between age group and clinicopathological
features
We divided the patients into two groups according to
whether they were 80 years or older (older group) or
Table 1 Correlations between EGFR mutations and clinicopathological features
Characteristics Total No. of patients
EGFR status pa KRAS status pa
Mutation Wild-type Mutation Wild-type
(n = 388) (n = 185, 47.7%) (n = 203, 52.3%) (n = 33, 8.5%) (n = 355, 91.5%)
Mean age, yr ± SDb 66.6 ± 10.0 65.1 ± 10.3 67.9 ± 9.57 0.462 68.6 ± 9.11 66.4 ± 10.1 0.553
Gender <0.001 0.552
Male 228 75 153 21 207
Female 160 110 50 12 148
Histological type <0.001 0.059
Adenocarcinoma 302 183 119 30 272
Others 86 2 84 3 83
Vascular invasion
Ly - 314 155 159 0.172 25 289 0.429
Ly + 74 30 44 8 66
V - 261 151 110 <0.001 23 238 0.756
V + 127 34 93 10 117
p-stage <0.001
I 293 155 138 22 271 0.217
II / III 95 30 65 11 84
T-factor <0.001
T1 197 114 83 14 183 0.316
T2 / 3 191 71 120 19 191
Tumor diameter (cm) 3.03 ± 1.43 2.68 ± 0.92 3.35 ± 1.71 <0.001 3.46 ± 1.99 2.99 ± 1.36 0.001
N-factor 0.348
N0 322 157 165 29 293 0.435
N1 / 2 66 28 38 4 62
Smoking status <0.001 0.107
Non-smoker 157 106 51 9 148
Smoker 231 79 152 24 207
Pre-existing cardiopulmonary comorbidity 203 86 117 0.028 20 183 0.319
ap < 0.05 statistically significant.
bSD, standard deviation.
EGFR, epidermal growth factor receptor; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; ND, lymph node dissection.
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EGFR status and clinicopathological features between
these age groups (Table 2). The younger group comprised
359 patients (92.5%), and the older group comprised 29
(7.5%). The proportion of patients with EGFR mutations
was significantly higher in the younger group (178/359,
49.6%) than in the older group (7/29, 24.1%; P = 0.008).
In contrast, KRAS mutations were more common in the
older group (6/29, 20.7%) than in the younger group
(27/359, 7.5%; P = 0.014). The proportion of smokers
was significantly lower in the younger group (208/359,
57.9%) than in the older group (23/29, 79.3%; P = 0.024).
Elderly patients had more pre-existing cardiopulmonary
comorbidities than younger patients (P = 0.024). Gender,
histopathological type, vascular invasion, pathologicalstage, and tumor diameter did not differ significantly
between the groups. We omitted lymph-node resection
in the older group (P < 0.001). Table 3 shows the region
of EGFR mutation according to age group. Although the
study group was small, there were no exon 20 mutations
in the older group.
Relations between EGFR status and outcomes
Kaplan-Meier curve analysis showed that EGFR muta-
tion status was significantly associated with survival
(Figure 1). The 5-year overall survival rate was signifi-
cantly higher in patients with EGFR mutations (90.2%)
than in those with wild-type EGFR (75.2%) in the youn-
ger group (P < 0.001; Figure 1A). The 5-year overall
survival rate was slightly, but not significantly higher
Table 2 Correlations between age group and clinicopathological features, including EGFR status
No. of patients
Characteristics Total ≥80 years <80 years pa
(n = 388) (n = 29, 7.5%) (n = 359, 92.5%)
Mean age, yr ± SDb 66.6 ± 10.0 82.6 ± 2.41 65.3 ± 9.29 <0.001
Gender 0.246
Male 228 20 208
Female 160 9 151
Histology 0.034
Adenocarcinoma 302 18 284
others 86 11 75
Biomarker
EGFR wild type 203 22 181 0.008
EGFR mutation 185 7 178
KRAS wild type 355 23 332 0.014
KRAS mutation 33 6 27
Vascular invasion
Ly - 314 26 288 0.214
Ly + 74 3 71
V - 261 18 243 0.535
V + 127 11 116
p-stage 0.080
I 293 18 275
II / III 95 11 84
T-factor 0.506
T1 197 13 184
T2/3 191 16 175
Tumor diameter (cm) 3.03 ± 1.43 3.00 ± 1.44 3.40 ± 1.24 0.629
N-factor 0.584
N0 322 23 299
N1/2 66 6 60
Operation 0.155
Limited resection (wedge/segmentectomy) 80 3 77
Standard surgery (lobectomy, pneumonectomy) 308 26 282
Lymph node resection <0.001
ND0/1/sampling 109 25 156
ND2 278 4 203
Smoking 0.024
Non-smoker 157 6 151
Smoker 231 23 208
Pre-existing cardiopulmonary comorbidity 203 21 182 0.024
ap < 0.05 statistically significant.
bSD, standard deviation.
EGFR, epidermal growth factor receptor; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; ND, lymph node dissection.
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wild-type EGFR (66.2%) in the older group (P = 0.226;
Figure 1B).Discussion
In the present study, we first evaluated EGFR mutations
in resected NSCLC tissue by LH-MSA. LH-MSA is a
Table 3 Region of EGFR mutation according to age group
No. of patients
EGFR mutations Total ≥80 years <80 years
Exon 19 73 3 70
Exon 20 13 0 13
Exon 21 97 4 93
Combined 2 0 2
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Sakuma et al. previously evaluated EGFR mutations by
LH-MSA in our hospital. EGFR mutations were detected
in 53.2% of NSCLCs and were significantly associated with
adenocarcinoma, female sex, and no smoking history [14].
In the present study, we detected EGFR mutations in
47.7% of NSCLCs (Table 1). The presence of an EGFR
mutation is closely linked to several clinicopathological
factors, such as gender, smoking history, and pathological
findings. Our results are consistent with those of recent
studies reporting that the rate of EGFR mutations is
higher among Asians (including Japanese), females,
nonsmokers, and adenocarcinomas [14,15]. Although
LH-MSA yet has not been generally performed, it is
known to be a sensitive and low cost method in scanning
the known gene mutation. Furthermore, we can treat
many samples in a short time by LH-MSA. Nakajima
et al. analyzed EGFR mutations using LH-MSA, and con-
firmed the results by direct sequencing. They concluded
that LH-MSA has a high detection capability compared
with direct sequencing [16]. Guideline from the College of
American Pathologists, International Association for the
Study of Lung Cancer, and Association for MolecularFigure 1 Relations between EGFR mutations and outcomes. Kaplan-Me
associated with survival. (A) The 5-year overall survival rate was higher in p
(75.2%) in the younger group (P < 0.001). (B) In the older group, the 5-year
mutations; however, the difference between the two groups was not signiPathology indicate that LH-MSA compares favourably
with the other method [17].
We then studied the relations between EGFR status
and clinicopathological factors according to age group
(Table 2). Past report suggested the impact of age on
EGFR mutation, and concluded that age was associated
with EGFR mutation in lung cancer [18]. In this study, if
we analyze the EGFR status using the median age of
66 years old as a cutoff, there is no difference between
younger and elderly group. Next, we divided the cohort
in every ten years old, and we found that the rate of
EGFR mutation suddenly decreased in a group 80 years
or older. Because aging of the population is a global
problem, the average life-span older than 80 years old in
Japan was worthy of mention to the world. Due to the
above reasons, we thought that the age of 80 years old is
turning point in consideration of gene profile change,
and divided the patients into two groups at 80 years of age.
The older group (≥80 years) of patients with NSCLC in-
cluded significantly higher rates of non-adenocarcinoma,
wild-type EGFR, KRAS mutations, and smokers. There was
no difference between the older group and younger group
in tumor size, T-factor, or pathological stage. Moreover, in
Japan, females outlive males (males 79 years, females
86 years). Of the 29 elderly patients, 9 are females include
7 adenocarcinomas and 4 smokers. EGFR mutations were
detected in 3 females. The 5-year overall survival rate was
100% regardless of EGFR mutation or wild type. When we
examined the region of EGFR mutation according to age
group (Table 3), no exon 20 mutations were found in the
older group. Although our study group was small, our
results suggest that EGFR mutation status might differier curve analysis showed that EGFR mutation status was significantly
atients with EGFR mutations (90.2%) than in those with wild-type EGFR
disease free survival rate was 100% among patients with EGFR
ficant.
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that smoking is one of the causes of the low rate of EGFR
mutations in the older group, the rate of EGFR mutations
may increase in the future owing to enlightenment
movements such as the WHO Framework Convention
on Tobacco Control [19]. Recently, smoking prevalence
in Japan is decreasing generally. In particular, the drop of
the smoking prevalence in young generation is remark-
able. On the other hands, lung cancer mortality in Japan
rises, probably it depends on the increase of the lung can-
cer in an elderly person who had been a smoker [20]. If
the low rate of EGFR mutations is unrelated to smoking,
it is very interesting that EGFR status might be affected by
aging. Furthermore, it is reported that the response rate of
gefitinib in elderly (aged 70 years or older) patients with
advanced EGFR mutated NSCLC was 45.5%. EGFR-TKI is
more effective than conventional chemotherapy in elderly
patients, if we could pay attention to drug discontinuation
and dose reduction due to age-related organ dysfunction
[21]. On the other hand, NSCLC with exon 20 mutation
is resistant for EGFR-TKI. Although our result has no
statistical significance due to a small population of eld-
erly patients, the lack of exon 20 mutations might be a
characteristic of elderly patients. Large clinical trials are
needed to investigate the relation between age group
and the response to EGFR-TKI.
Finally, we assessed the relations between the EGFR
status and outcomes. EGFR mutations were associated with
significantly better survival than wild-type EGFR in the
younger group (Figure 1). In the older group, however, the
5-year overall survival rate did not differ significantly ac-
cording to EGFR mutations, and wild-type EGFR status
and was 100% in patients with EGFR mutations. EGFR-
TKIs are obviously beneficial in patients with advanced or
recurrent NSCLC, but several studies have suggested that
EGFR mutations might be an independent positive prog-
nostic factor [22]. Our results suggest that elderly patients
with NSCLC who have EGFRmutations are especially likely
to have good outcomes after complete lung resection.
Conclusion
Our results suggest that the EGFR status of patients
with NSCLC differs according to age group (>80 years
vs. ≤80 years). EGFR mutation status might be a prognos-
tic marker in elderly patients with completely resected
NSCLC.
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